Reimbursement Review Reports
( Last Updated : March 24, 2023)
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
| Anoro Ellipta | Umeclidinium/vilanterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
| Apidra | Insulin glulisine | Diabetes, Mellitus (Type 1 & 2) | List in a similar manner to other drugs in class | Complete | ||
| Apprilon | Doxycycline monohydrate | Rosacea | Do not list | Complete | ||
| Aptiom | Eslicarbazepine acetate | Epilepsy, partial-onset seizures | List with criteria/condition | Complete | ||
| Aptivus | Tipranavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
| Arbesda RespiClick | fluticasone propionate / salmeterol xinafoate | Asthma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Arnuity Ellipta | Fluticasone furoate | Asthma | List with criteria/condition | Complete | ||
| Arzerra | Ofatumumab | Chronic Lymphocytic Leukemia | Do not reimburse | Complete |